超级碰在线-超级碰碰永久免费视频播放-超级碰碰碰免费视频播放-超级碰碰碰免费视频-亚洲国产99在线精品一区69堂-亚洲高清资源在线观看

加拿大Resverlogix  
Resverlogix Corp. (TSX: RVX) 是一家心血管疾病臨床研究公司，公司擁有能夠調(diào)節(jié)蛋白質(zhì)形成的表觀遺傳學(xué)平臺技術(shù)。Resverlogix 正在開發(fā) RVX-208——用于治療動脈粥樣硬化的同類首個小分子。RVX-208 是首個正在進(jìn)行臨床試驗的 BET 溴區(qū)結(jié)構(gòu)域抑制劑。出自 Resverlogix 表觀遺傳學(xué)藥物發(fā)現(xiàn)平臺的新復(fù)合制劑通過抑制 BET 溴區(qū)結(jié)構(gòu)域而發(fā)揮作用，并有希望用來治療癌癥、自身免疫性疾病和神經(jīng)退行性疾病等多種病癥。Resverlogix 的普通股在多倫多證券交易所交易 (TSX: RVX)。

Resverlogix Corp. is a publicly traded biotechnology company (TSX:RVX) engaged in the development of novel therapies for important global medical markets with significant unmet medical needs. The NexVas? Plaque Regression program is the Company's primary focus which is to develop novel small molecules that enhance ApoA-I production. These vital therapies are focused to address the burden of atherosclerosis and other important diseases such as Acute Coronary Syndrome, Alzheimer's disease, Peripheral Artery Disease and Autoimmune diseases.

Our Business Model is to seek strategic opportunities through early alliance partnerships that are best suited to bring our technology platforms to successful commercialization. We are committed to good corporate governance and protection of shareholder value.